Get the Stockscreener App
46.61
2.10%
0.96
After Hours:
46.61
Prestige Consumer Healthcare Inc stock is traded at $46.61, with a volume of 467.65K.
It is up +2.10% in the last 24 hours and down -9.41% over the past month.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
See More
Previous Close:
$45.65
Open:
$45.34
24h Volume:
467.65K
Relative Volume:
0.83
Market Cap:
$2.21B
Revenue:
$1.10B
Net Income/Loss:
$186.50M
P/E Ratio:
12.33
EPS:
3.7817
Net Cash Flow:
$267.19M
1W Performance:
+3.65%
1M Performance:
-9.41%
6M Performance:
-23.75%
1Y Performance:
-25.69%
1-Day Range:
$44.97
$46.72
1-Week Range:
$44.46
$47.80
52-Week Range:
$42.62
$71.07
Prestige Consumer Healthcare Inc Stock (PBH) Company Profile
Name
Prestige Consumer Healthcare Inc
Sector
Phone
(914) 524-6800
Address
660 WHITE PLAINS RD., TARRYTOWN, NY
Compare PBH vs TAK, TEVA, HLN, ZTS, VTRS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBH
Prestige Consumer Healthcare Inc
|
46.61 | 2.21B | 1.10B | 186.50M | 267.19M | 3.7817 |
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.05 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
17.83 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Prestige Consumer Healthcare Inc Stock (PBH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-25 | Upgrade | Sidoti | Neutral → Buy |
| Dec-09-24 | Downgrade | Sidoti | Buy → Neutral |
| Jun-21-24 | Upgrade | DA Davidson | Neutral → Buy |
| Nov-17-22 | Initiated | Canaccord Genuity | Buy |
| May-10-22 | Upgrade | Jefferies | Hold → Buy |
| May-09-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-07-20 | Downgrade | DA Davidson | Buy → Neutral |
| Jun-29-20 | Upgrade | Sidoti | Neutral → Buy |
| Apr-14-20 | Downgrade | Jefferies | Buy → Hold |
| Apr-07-20 | Resumed | Sidoti | Neutral |
| Mar-26-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-24-20 | Initiated | Oppenheimer | Perform |
| Mar-19-20 | Upgrade | DA Davidson | Neutral → Buy |
| Jan-15-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-04-17 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-02-17 | Upgrade | Jefferies | Underperform → Hold |
| May-22-17 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Dec-27-16 | Reiterated | B. Riley & Co. | Buy |
| Nov-17-16 | Initiated | Gabelli & Co | Buy |
| Aug-12-16 | Upgrade | Sidoti | Neutral → Buy |
| Mar-08-16 | Initiated | KeyBanc Capital Mkts | Overweight |
| Feb-05-16 | Initiated | Piper Jaffray | Overweight |
| Nov-30-15 | Downgrade | Jefferies | Hold → Underperform |
| Apr-28-14 | Reiterated | B. Riley & Co. | Buy |
| Apr-28-14 | Reiterated | Oppenheimer | Outperform |
| Jul-09-13 | Initiated | B. Riley & Co. | Buy |
View All
Prestige Consumer Healthcare Inc Stock (PBH) Latest News
Prestige Consumer Healthcare at small-cap virtual conference: growth plan intact - Investing.com India
Prestige Consumer Healthcare Inc. (PBH) Stock Price, News, Quote & History - Yahoo! Finance Canada
Prestige Consumer Healthcare In (PBH) Stock Forecasts - Yahoo Finance
A Look at Prestige Consumer Healthcare Inc (PBH) After 3.8% Decl - GuruFocus
Responsive Playbooks and the PBH Inflection - Stock Traders Daily
Prestige Consumer Healthcare stock gains ahead of Sidoti event - AD HOC NEWS
Prestige Consumer Healthcare Inc. (PBH) Stock Analysis: 50% Upside Potential Amid Steady Revenue Growth - DirectorsTalk Interviews
Prestige Consumer Healthcare stock falls as analysts stay cautious - AD HOC NEWS
Prestige Consumer Healthcare stock falls after sharp drop toward 52-week low - AD HOC NEWS
Prestige Consumer Healthcare Inc (PBH) Shares Fall 3.2% -- What GF Score of 65 Tells Investors - GuruFocus
Prestige Consumer Healthcare stock holds steady as investors focus on recent earnings trend - AD HOC NEWS
PBH: Portfolio expansion and brand integration drive growth, with Clear Eyes recovery a key focus - TradingView
Prestige Consumer Healthcare at Barclays conference: growth via niche brands - Investing.com Canada
How InvestingPro Fair Value spotted Prestige Healthcare’s 43% drop By Investing.com - Investing.com India
Prestige Consumer Healthcare Inc. to Participate in Barclays Global Consumer Conference - The Manila Times
Prestige Consumer Healthcare Inc. (PBH) Stock Analysis: Assessing a Promising 29.74% Potential Upside - DirectorsTalk Interviews
Is This the Right Time to Add PBH Stock to Your Portfolio? - TradingView
Precision Trading with Prestige Consumer Healthcare Inc. (PBH) Risk Zones - Stock Traders Daily
Prestige Consumer Healthcare stock holds steady as investors watch valuation and growth - AD HOC NEWS
Football Stress May Be Following Fans to Bed, According to the Inaugural DenTek® Football Stress Test - Financial Times
Prestige Consumer Healthcare Inc. (PBH) Stock Analysis: Exploring A 29% Upside Potential - DirectorsTalk Interviews
PBH Q2 2026 Earnings: EPS Beats Estimates by 10.01% as Stock Advances 2.46%Profit Guidance Range - dars.gov.et
PBH vs. SYK: Which Stock Is the Better Value Option? - Yahoo Finance
Prestige Consumer Healthcare Inc. (PBH) Investor Outlook: Exploring a 32% Upside Potential - DirectorsTalk Interviews
40,000 eye drop bottles recalled over potential contamination - Oman Observer
Nearly 40,000 eye drop bottles are recalled over potential contamination - The Seattle Times
40,000 bottles of eye drops across the US recalled over issues with sterility of product - inkl
Clear Eyes Maximum Itchy Eye Relief Recall: FDA Announces 39,060 Bottles RecalledNews and Statistics - IndexBox
Nearly 40,000 eye drops recalled nationwide over possible contamination - Fox Business
Great Lakes Advisors LLC Takes $2.98 Million Position in Prestige Consumer Healthcare Inc. $PBH - MarketBeat
Nearly 40,000 bottles of eye drops recalled nationwide over possible contamination - FOX 32 Chicago
Clear Eyes eye drops recalled over sterility concerns - qz.com
FDA announces nationwide recall of nearly 40,000 Clear Eyes eye-drop bottles over potential contamination - The Economic Times
Is Prestige Consumer Healthcare’s (PBH) Upgraded 2027 Outlook and Halted Buybacks Reframing Its Growth Story? - webull.com
Rice Hall James & Associates LLC Acquires Shares of 689,692 Prestige Consumer Healthcare Inc. $PBH - MarketBeat
FDA recalls over 39K bottles of CLEAR EYES Maximum Itchy Relief drops - Glance by Eyes On Eyecare
Prestige Consumer Healthcare (PBH) Q1 2027 Earnings Call Transcript - AOL.com
Prestige Consumer Healthcare (PBH) Stock Analysis: Exploring a 31.96% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Prestige Consumer Healthcare (PBH) Holds Near $51.38 as Range-Bound Trading PersistsVolume Dry Up - vinanet.vn
ETFs Investing in Prestige Consumer Healthcare Inc Stocks - TradingView
Prestige Consumer Healthcare Announces Operations Leadership Transition - The Globe and Mail
Prestige Consumer Healthcare's Jeffrey Zerillo to Retire as SVP, Operations - TradingView
Prestige Consumer Healthcare Inc. Announces Retirement of Jeffrey Zerillo from Senior Vice President, Operations, Effective August 14, 2026 - marketscreener.com
Prestige Consumer Healthcare (PBH) Bets Big On M&A, But Can Clear Eyes Recover? - Yahoo Finance
Prestige Consumer Healthcare Inc Stock (PBH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):